deltatrials
Completed PHASE4 INTERVENTIONAL 2-arm NCT02874287

Efficacy Study of Hydroxychloroquine to Treat High-risk Coronary Artery Disease. (CHANGAN)

Hydroxychloroquine Assessment of Management Study in Coronary Artery Disease After Angiography.

Sponsor: First Affiliated Hospital Xi'an Jiaotong University

Updated 10 times since 2017 Last updated: Aug 26, 2021 Started: Oct 8, 2017 Primary completion: Mar 1, 2019 Completion: Jun 1, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02874287, this PHASE4 trial focuses on Coronary Artery Disease and remains completed. Sponsored by First Affiliated Hospital Xi'an Jiaotong University, it has been updated 10 times since 2017, reflecting substantial change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Study Description(click to expand)

This double blind, placebo, randomized controlled trial is going to assess if hydroxychloroquine could improve the high sensitivity C-reaction protein, blood lipid, blood glucose and blood pressure, also whether hydroxychloroquine could affect the secretion of inflammatory cytokines and the M1/M2 phenotype polarization of macrophages in patients with high-risk coronary artery disease.

This double blind, placebo, randomized controlled trial is going to assess if hydroxychloroquine could improve the high sensitivity C-reaction protein, blood lipid, blood glucose and blood pressure, also whether hydroxychloroquine could affect the secretion of inflammatory cytokines and the M1/M2 phenotype polarization of macrophages in patients with high-risk coronary artery disease.

Status Flow

~Jan 2017 – ~Dec 2017 · 11 months · monthly snapshotNot Yet Recruiting~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshotRecruiting~Jun 2018 – ~Dec 2019 · 18 months · monthly snapshotRecruiting~Dec 2019 – ~Jan 2021 · 13 months · monthly snapshotUnknown Status~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshotUnknown Status~Sep 2021 – ~Jul 2024 · 34 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotCompleted~Sep 2025 – present · 7 months · monthly snapshotCompleted~Jan 2026 – present · 3 months · monthly snapshotCompleted

Change History

10 versions recorded
  1. Jan 2026 — Present [monthly]

    Completed PHASE4

  2. Sep 2025 — Present [monthly]

    Completed PHASE4

  3. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE4

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE4

  5. Sep 2021 — Jul 2024 [monthly]

    Completed PHASE4

    Status: Unknown StatusCompleted

Show 5 earlier versions
  1. Jan 2021 — Sep 2021 [monthly]

    Unknown Status PHASE4

  2. Dec 2019 — Jan 2021 [monthly]

    Unknown Status PHASE4

    Status: RecruitingUnknown Status

  3. Jun 2018 — Dec 2019 [monthly]

    Recruiting PHASE4

  4. Dec 2017 — Jun 2018 [monthly]

    Recruiting PHASE4

    Status: Not Yet RecruitingRecruiting

  5. Jan 2017 — Dec 2017 [monthly]

    Not Yet Recruiting PHASE4

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • First Affiliated Hospital Xi'an Jiaotong University
Data source: First Affiliated Hospital Xi'an Jiaotong University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations